中国全科医学2025，Vol.28Issue(36)：4550-4557,8.DOI:10.12114/j.issn.1007-9572.2025.0046
意大利科学联盟立场声明解读:药物审查和处方精简
Interpretation of a Position Statement from an Italian Scientific Consortium:Medication Review and Deprescribing
摘要
Abstract
Multimorbidity often leads to polypharmacy,increasing the risk of drug interactions and adverse drug reactions.Medication review and deprescribing are crucial strategies for improving therapeutic regimens,aiming to enhance patients'overall health and quality of life through reviewing and reducing inappropriate medication use.In March 2024,the Italian Scientific Consortium issued a position statement on medication review and deprescribing,outlining their key elements,methods,available tools,and clinical value.Based on an analysis of this statement,this article introduces the concepts and objectives of medication review and deprescribing.It elaborates on the main processes from four aspects:comprehensive medication history review,medication therapy assessment,multidisciplinary medication therapy planning,and follow-up.The article reviews implementation outcomes across different healthcare settings,analyzes challenges and coping strategies in China,and aims to provide theoretical support for promoting medication review and deprescribing by clinicians for their patients.关键词
药物处方/药物审查/处方精简/多重用药/不适当用药/立场声明/解读Key words
Drug prescriptions/Medication review/Deprescribing/Polypharmacy/Inappropriate medications/Position statement/Interpretation分类
医药卫生引用本文复制引用
孙佳颖,周鹏翔,夏瑀,严明,周馨媚,吴玲燕,童钰铃,赵洋,徐志杰..意大利科学联盟立场声明解读:药物审查和处方精简[J].中国全科医学,2025,28(36):4550-4557,8.基金项目
国家自然科学基金资助项目(72304008) （72304008）
浙江省医药卫生科技计划(2023KY748,2024KY1026) （2023KY748,2024KY1026）
国家重点研发计划(2022YFF0902004) （2022YFF0902004）
